A small molecule inhibitor of dengue virus type 2 protease inhibits the replication of all four dengue virus serotypes in cell culture

Virology Journal

Sathyamangalam Swaminathan³  Dharmarajan Sriram³  Perumal Yogeeswari³  Variam U Jeankumar⁴  Swatantra K Jain¹  Ira Khanna⁵  Poornima Tyagi²  Hemalatha Beesetti⁶  Rajendra Raut¹ 

[1] Department of Biotechnology, Jamia Hamdard, Hamdard Nagar, New Delhi 110062, India;Recombinant Gene Products Group, International Centre for Genetic Engineering and Biotechnology, New Delhi 110067, India;Centre for Infectious Disease Research, Birla Institute of Technology and Science Pilani, Hyderabad Campus, Hyderabad 500078, India;Department of Pharmacy, Birla Institute of Technology and Science Pilani, Hyderabad Campus, Hyderabad 500078, India;Department of General Medicine, Lady Hardinge Medical College, Shaheed Bhagat Singh Marg, New Delhi 110001, India;Department of Biological Sciences, Birla Institute of Technology and Science Pilani, Hyderabad Campus, Hyderabad 500078, India

关键词: Antiviral therapy;    Dengue protease inhibitor;    NS2b-NS3 protease;    Dengue virus;    Dengue fever;   

Others  :  1131016
DOI  :  10.1186/s12985-015-0248-x

 received in 2014-11-18, accepted in 2015-01-22,  发布年份 2015

【 摘 要 】

Background

Dengue has emerged as the most significant of arboviral diseases in the 21st century. It is endemic to >100 tropical and sub-tropical countries around the world placing an estimated 3.6 billion people at risk. It is caused by four genetically similar but antigenically distinct, serotypes of dengue viruses. There is neither a vaccine to prevent nor a drug to treat dengue infections, at the present time. The major objective of this work was to explore the possibility of identifying a small molecule inhibitor of the dengue virus protease and assessing its ability to suppress viral replication in cultured cells.

Methods

We cloned, expressed and purified recombinant dengue virus type 2 protease. Using an optimized and validated fluorogenic peptide substrate cleavage assay to monitor the activity of this cloned dengue protease we randomly screened ~1000 small molecules from an ‘in-house’ library to identify potential dengue protease inhibitors.

Results

A benzimidazole derivative, named MB21, was found to be the most potent in inhibiting the cloned protease (IC₅₀ = 5.95 μM). In silico docking analysis indicated that MB21 binds to the protease in the vicinity of the active site. Analysis of kinetic parameters of the enzyme reaction suggested that MB21 presumably functions as a mixed type inhibitor. Significantly, this molecule identified as an inhibitor of dengue type 2 protease was also effective in inhibiting each one of the four serotypes of dengue viruses in infected cells in culture, based on analysis of viral antigen synthesis and infectious virus production. Interestingly, MB21 did not manifest any discernible cytotoxicity.

Conclusions

This work strengthens the notion that a single drug molecule can be effective against all four dengue virus serotypes. The molecule MB21 could be a potential candidate for ‘hit-to-lead’ optimization, and may pave the way towards developing a pan-dengue virus antiviral drug.

【 授权许可】

   
2015 Raut et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Gubler DJ: The economic burden of dengue. Am J Trop Med Hyg 2012, 86:743-744.
• [2]Guzman MG, Halstead SB, Artsob H, Buchy P, Farrar J, Gubler DJ, et al. Dengue: a continuing global threat. Nat Rev Microbiol 2010, Dec Supplement, S7-S16.
• [3]Swaminathan S, Khanna N: Dengue: recent advances in biology and current status of translational research. Curr Mol Med 2009, 9:152-173.
• [4]Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, et al.: The global distribution and burden of dengue. Nature 2013, 496:504-507.
• [5]Lindenbach BD, Thiel HJ, Rice CM: Flaviviridae: the viruses and their replication. In Field’s Virology. 5th edition. Edited by Knipe DM, Howley PM. Wolters Kluwer and Lippincott Williams & Wilkins, Philadelphia; 2007:1101-1152.
• [6]World Health Organization: Factsheet No117: Dengue and dengue haemorrhagic fever. 2014. [www.who.int/mediacentre/factsheets/fs117/en/]
• [7]Swaminathan S, Batra G, Khanna N: Dengue vaccines: state of the art. Exp Opin Ther Patents 2010, 20:819-835.
• [8]Swaminathan S, Khanna N: Experimental dengue vaccines. In Molecular Vaccine-from prophylaxis to therapy. Edited by Giese M. Springer-Verlag, Heidelberg; 2013:135-151.
• [9]Capeding MR, Tran NH, Hadinegoro SRS, Ismail HIHJM, Chotpitayasunondh T, Chua MN, et al.: Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomized, observer-masked, placebo-controlled trial. Lancet 2014, 384:1358-1365.
• [10]Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, et al.: Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomized, controlled phase 2b trial. Lancet 2012, 380:1559-1567.
• [11]Swaminathan S, Khanna N, Herring B, Mahalingam S: Dengue vaccine efficacy trial: does interference cause failure? Lancet Infect Dis 2013, 13:191-192.
• [12]Lim SP, Wang QY, Noble CG, Chen YL, Dong H, Zou B, et al.: Ten years of dengue drug discovery: progress and prospects. Antiviral Res 2013, 100:500-519.
• [13]Noble CG, Chen YL, Dong H, Gu F, Lim SP, Schul W, et al.: Strategies for development of dengue virus inhibitors. Antiviral Res 2010, 85:450-462.
• [14]Libraty DH, Endy TP, Houng HSH, Greene S, Kalyanarooj S, Suntayakorn S, et al.: Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis 2002, 185:1213-1221.
• [15]Vaughn DW, Greene S, Kalayanarooj S, Innis BL, Nimmanitya S, Suntayakorn S, et al.: Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis 2000, 181:2-9.
• [16]Lescar J, Luo D, Xu T, Sampath A, Lim SP, Canard B, et al.: Towards the design of antiviral inhibitors against flaviviruses: the case for the multifunctional NS3 protein from dengue virus as a target. Antiviral Res 2008, 80:94-101.
• [17]Falgout B, Miller RH, Lai CJ: Deletion analysis of dengue virus type 4 nonstructural protein NS2b: identification of a domain required for NS2b-NS3 protease activity. J Virol 1993, 67:2034-2042.
• [18]Chambers TJ, Weir RC, Grakoui A, McCourt DW, Bazan JF, Fletterick RJ, et al.: Evidence that the N-terminal domain of nonstructural protein NS3 from yellow fever virus is a serine protease responsible for site-specific cleavage in the viral polyprotein. Proc Natl Acad Sci USA 1990, 87:8898-8902.
• [19]Chambers TJ, Nestorowicz A, Amberg SM, Rice CM: Mutagenesis of the yellow fever virus NS2b protein: effects on proteolytic processing, NS2b-NS3 complex formation, and viral replication. J Virol 1993, 67:6797-6807.
• [20]Li J, Lim SP, Beer D, Patel V, Wen D, Tumanut C, et al.: Functional profiling of recombinant NS3 proteases from all four serotypes of dengue virus using tetrapeptide and octapeptide substrate libraries. J Biol Chem 2005, 280:28766-28774.
• [21]Leung D, Schroder K, White H, Fang NX, Stoermer MJ, Abbenante G, et al.: Activity of recombinant dengue 2 virus NS3 protease in the presence of a truncated NS2b co-factor, small peptide substrates, and inhibitors. J Biol Chem 2001, 276:45762-45771.
• [22]Yusof R, Clum S, Wetzel M, Murthy HMK, Padmanabhan R: Purified NS2B/NS3 serine protease of dengue virus type 2 exhibits cofactor NS2B dependence for cleavage of substrates with dibasic amino acids in vitro. J Biol Chem 2000, 275:9963-9969.
• [23]Jean Kumar VU, Poyraz O, Saxena S, Schnell R, Yogeeswari P, Schneider G, et al.: Discovery of novel inhibitors targeting the Mycobacterium tuberculosis O-acetylserine sulfhydrylase (CysK1) using virtual high-throughput screening. Biorg Med Chem Lett 2013, 23:1182-1186.
• [24]Poyraz O, Jeankumar VU, Saxena S, Schnell R, Haraldsson M, Yogeeswari P, et al.: Structure-guided design of novel thiazolidine inhibitors of O-acetyl serine sulfhydrylase from Mycobacterium tuberculosis. J Med Chem 2013, 56:6457-6466.
• [25]Mukhametov A, Newhouse EI, Aziz NA, Saito JA, Alam M: Allosteric pocket of the dengue virus (serotype 2) NS2B/NS3 protease: In silico ligand screening and molecular dynamics studies of inhibition. J Mol Graph Model 2014, 52:103-113.
• [26]Othman R, Kiat TS, Khalid N, Yusof R, Newhouse EI, Newhouse JS, et al.: Docking of noncompetitive inhibitors into dengue virus type 2 protease: understanding the interactions with allosteric binding sites. J Chem Inf Model 2008, 48:1582-1591.
• [27]Korrapati AB, Swaminathan G, Singh A, Khanna N, Swaminathan S: Adenovirus-delivered short hairpin RNA targeting a conserved site in the 5’ non-translated region inhibits all four serotypes of dengue viruses. PLoS Negl Trop Dis 2012, 6:e1735.
• [28]Ludert JE, Mosso C, Ceballos-Olvera I, del Angel RM: Use of a commercial enzyme immunoassay to monitor dengue virus replication in cultured cells. Virol J 2008, 5:51. BioMed Central Full Text
• [29]Schul W, Liu W, Xu HY, Flamand M, Vasudevan SG: A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J Infect Dis 2007, 195:665-674.
• [30]Yildiz M, Ghosh S, Bell JA, Sherman W, Hardy JA: Allosteric inhibition of the NS2b-NS3 protease from dengue virus. ACS Chem Biol 2013, 8:2744-2752.
• [31]Heaton NS, Perera R, Berger KL, Khadka S, LaCount DJ, Kuhn RJ, et al.: Dengue virus non-structural protein 3 redistributes fatty acid synthase to sites of viral replication and increases cellular fatty acid synthesis. Proc Natl Acad Sci USA 2010, 107:17345-17350.
• [32]Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, et al.: Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004, 47:1739-1749.